Key Takeaways
- “Prior to the whole tariffs … given the momentum that we were seeing in the base business, we were already considering raising our EPS guidance,” says Abbott CEO Robert Ford.
- Although the president has exempted pharmaceuticals and some dietary ingredients, “botanicals, probiotics and omega-3s are not” included “because these dietary ingredients are not typically used in pharmaceuticals.”
- RBC analysts say even considering tariffs may have “double the impact for 2026, it is likely that the company will have ways to lessen the impact.”
Abbott’s consumer health footprint isn’t as large as other firms focused entirely or largely on the market, but management’s commentary on its latest results likely reflects what’s to come from...
“As we progress through 2025, it is clear that we are operating in an increasingly dynamic environment,” said CEO Robert Ford during Abbott’s first-quarter earnings briefing on 16 April.